Navigation Links
ADVENTRX Announces Further Cost-Cutting Measures
Date:1/5/2009

- 55% Reduction in Staff Since Start of Q4 2008

- Evaluation of strategic alternatives on-going

- Executive VP Steps Down and Resumes Board Role

SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Alternext US: ANX) announced today that it has implemented a further reduction-in-force in an effort to extend its remaining cash and to prepare itself for a strategic transaction. This follows a reduction implemented in October 2008. In all, the Company's workforce has declined by approximately 55% since the beginning of the fourth quarter of 2008. Following the current reduction and other planned departures, the Company will have fourteen employees. In addition, the Company has substantially reduced or delayed spending on third-party consulting and vendor services, including contract manufacturing.

ADVENTRX's remaining employees will focus their efforts on continuing to evaluate strategic options, as well as continuing the Company's on-going bioequivalence study of ANX-514 (docetaxel emulsion) and activities related to submitting a New Drug Application for ANX-530 (vinorelbine emulsion). The cost-cutting measures announced today should not have a direct and immediate effect on the Company's previously announced timelines. However, any further cost-reductions or expense reductions/delays likely will have a negative impact the Company's development and commercialization plans.

As part of its overall cost-cutting measures, Mark N. K. Bagnall, who in April 2008 joined the Company as Executive Vice President and Chief Financial Officer, agreed to return to his prior role as solely a member of the Company's Board of Directors, and has agreed to provide consulting services on an as-needed basis.

"It's never easy to let go employees, particularly those who have been with the Company for many years and who have made contributions to the Company. Tho
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. ADVENTRX Exploring Strategic Options
2. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
3. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
4. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
5. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
6. ADVENTRX Settles Dispute With Former Licensee
7. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. ADVENTRX Appoints Vice President of Manufacturing
9. ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
10. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
11. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... The third edition of Infusion Nursing: ... by the Infusion Nurses Society (INS), includes Totect(®), ... Anthracyclines are a group of chemotherapy medications including ... used in the treatment of various types of ... According to the INS publication: "In September 2007, ...
(Date:12/14/2009)... US-based thermoforming company, has completed the delivery of Brookfield Engineering’s ... to a plastic enclosure with a smaller footprint and more ... ... (PRWEB) December 14, 2009 -- ThermoFab, a US-based thermoforming company, ... – helping Brookfield move from sheet metal to a plastic ...
(Date:12/11/2009)... Leuven, 10 December 2009 -- Researchers have discovered a new ... males. The more excess copies of a certain gene, the ... the X-chromosome; and it is suspected that it is the ... The results are being published in the American Journal ... by the group of Guy Froyen connected to VIB, a ...
(Date:12/11/2009)... Gwathmey, Inc., a pre-clinical contract research ... aureus, and cardiovascular disease announces a new CEO. ... Rosalie Dunn, Ph.D., has joined Gwathmey as Chief ... years of experience working with small businesses and ... Dr. Dunn managed multimillion dollar portfolios for the ...
Breaking Biology Technology:Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2Amount of gene surplus determines severity of mental retardation in males 2Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2
... human cells back to a pluripotent or stem cell ... social challenges to the use of embryo-derived stem cells ... research with mouse and human cells has demonstrated that ... process is inefficient and, when it does work, poorly ...
... GPRO ) announced today that the Company has launched ... diagnostic test to detect,high-risk strains of the human papillomavirus ... been CE marked and is currently available,for sale in ... launch of our APTIMA HPV Assay in Europe reflect,Gen-Probe,s ...
... SAN DIEGO, May 28 Sequenom, Inc. (Nasdaq:,SQNM) today announced that ... its analyst and investor briefing event,"Sequenom: The Future of Noninvasive Prenatal ... Sequenom: The Future of Noninvasive Prenatal Diagnostics, ... 6:00 p.m. Pacific time, Where: http://www.sequenom.com ...
Other Biology Technology:New insights into cellular reprogramming revealed by genomic analysis 2Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 2Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 3Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 4Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 5Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3 2
(Date:12/15/2009)... a standard laboratory model organism, but there are ... analyze blood and blood-forming tissues in this species. ... easy-to-use laboratory resources from Cold Spring Harbor Laboratory ... features step-by-step protocols for the preparation, enumeration, ... and other hematopoietic tissues in the mouse. ...
(Date:12/14/2009)... fuel that could help wean the nation from oil, ... with gasoline, especially in winter, according to a new ... from both gasoline and E85, a blend of gasoline ... in warm sunny weather than during the cold weather ... contribute to ozone formation. But E85 produces different byproducts ...
(Date:12/14/2009)... (INTA-CSIC) has shown that hydrogen cyanide, urea and other ... basic biological molecules can be obtained from the salt ... published in the journal Chemistry & Biodiversity , ... Earth. , "We have shown that when Prussian blue ... a substance that could have played a fundamental role ...
Breaking Biology News(10 mins):New source of classical techniques for blood-based studies in the laboratory mouse 2Ethanol-powered vehicles generate more ozone than gas-powered ones 2Ethanol-powered vehicles generate more ozone than gas-powered ones 3Prussian blue linked to the origin of life 2Allied Worlds Nicole Baummer to Speak on Panel at National Employment Practices Liability Insurance ExecuSummit 57517 1Allied Worlds Nicole Baummer to Speak on Panel at National Employment Practices Liability Insurance ExecuSummit 57517 2Allied Worlds Nicole Baummer to Speak on Panel at National Employment Practices Liability Insurance ExecuSummit 57517 3Baucus Approach to Financing Health Care Reform Step in Right Direction 57515 1Baucus Approach to Financing Health Care Reform Step in Right Direction 57515 2Bolder BioTechnology Receives 241 2 Million NIH Grant to Continue Development of Long Acting EPO Analog for Chronic Kidney Disease 14125 1Bolder BioTechnology Receives 241 2 Million NIH Grant to Continue Development of Long Acting EPO Analog for Chronic Kidney Disease 14125 2Bolder BioTechnology Receives 241 2 Million NIH Grant to Continue Development of Long Acting EPO Analog for Chronic Kidney Disease 14125 3Bolder BioTechnology Receives 241 2 Million NIH Grant to Continue Development of Long Acting EPO Analog for Chronic Kidney Disease 14125 4
... respiratory infections, the body typically produces a little fluid to ... suggests that the influenza virus can tip the balance toward ... of oxygen to the rest of the body. , An ... this research suggests that it,s not the presence of the ...
... The genome of a marine bacterium living 2,500 meters ... life adapts in extreme thermal and chemical gradients, according ... PLoS Genetics , an open-access publication published by ... on the bacterium Nautilia profundicola , a microbe ...
... Plants are flowering at higher elevations in Arizona,s Santa ... research from The University of Arizona in Tucson. , ... during 1994 to 2003, compared to where the same ... study period, summer temperatures in the region increased about ...
Other Biology News:Study: Fluid buildup in lungs is part of the damage done by the flu 2Study: Fluid buildup in lungs is part of the damage done by the flu 3Genetic adaptations key to microbe's survival in challenging environment 2Plants take a hike as temperatures rise 2Plants take a hike as temperatures rise 3
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Rabbit polyclonal to MAP3K12 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH from the C-terminal region of human MAP3K12 Entrez Gene ID: 7786 Swiss ...
Mouse monoclonal [SIT-01] to SIT ( Abpromise for all tested applications). entrezGeneID: 27240 SwissProtID: Q9Y3P8...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Biology Products: